Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma

NCT03323710 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Poor patient recruitment.

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Propranolol
DRUG: Sunitinib

Sponsor

Military Institute od Medicine National Research Institute